123 related articles for article (PubMed ID: 29432024)
1. Evaluation of MUC1-Aptamer Functionalized Hybrid Nanoparticles for Targeted Delivery of miRNA-29b to Nonsmall Cell Lung Cancer.
Perepelyuk M; Sacko K; Thangavel K; Shoyele SA
Mol Pharm; 2018 Mar; 15(3):985-993. PubMed ID: 29432024
[TBL] [Abstract][Full Text] [Related]
2. Aptamer-hybrid nanoparticle bioconjugate efficiently delivers miRNA-29b to non-small-cell lung cancer cells and inhibits growth by downregulating essential oncoproteins.
Perepelyuk M; Maher C; Lakshmikuttyamma A; Shoyele SA
Int J Nanomedicine; 2016; 11():3533-44. PubMed ID: 27555773
[TBL] [Abstract][Full Text] [Related]
3. Codelivery of Genistein and miRNA-29b to A549 Cells Using Aptamer-Hybrid Nanoparticle Bioconjugates.
Sacko K; Thangavel K; Shoyele SA
Nanomaterials (Basel); 2019 Jul; 9(7):. PubMed ID: 31340494
[TBL] [Abstract][Full Text] [Related]
4. Anticancer role of MUC1 aptamer-miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation.
Dai F; Zhang Y; Zhu X; Shan N; Chen Y
Target Oncol; 2012 Dec; 7(4):217-25. PubMed ID: 23179556
[TBL] [Abstract][Full Text] [Related]
5. The mechanism involved in the loss of PTEN expression in NSCLC tumor cells.
Li G; Zhao J; Peng X; Liang J; Deng X; Chen Y
Biochem Biophys Res Commun; 2012 Feb; 418(3):547-52. PubMed ID: 22290228
[TBL] [Abstract][Full Text] [Related]
6. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.
Huang X; Schwind S; Yu B; Santhanam R; Wang H; Hoellerbauer P; Mims A; Klisovic R; Walker AR; Chan KK; Blum W; Perrotti D; Byrd JC; Bloomfield CD; Caligiuri MA; Lee RJ; Garzon R; Muthusamy N; Lee LJ; Marcucci G
Clin Cancer Res; 2013 May; 19(9):2355-67. PubMed ID: 23493348
[TBL] [Abstract][Full Text] [Related]
7. The anti-chemoresistant effect and mechanism of MUC1 aptamer-miR-29b chimera in ovarian cancer.
Dai F; Zhang Y; Zhu X; Shan N; Chen Y
Gynecol Oncol; 2013 Nov; 131(2):451-9. PubMed ID: 23933187
[TBL] [Abstract][Full Text] [Related]
8. A novel MUC1 aptamer-modified PLGA-epirubicin-PβAE-antimir-21 nanocomplex platform for targeted co-delivery of anticancer agents in vitro and in vivo.
Bahreyni A; Alibolandi M; Ramezani M; Sarafan Sadeghi A; Abnous K; Taghdisi SM
Colloids Surf B Biointerfaces; 2019 Mar; 175():231-238. PubMed ID: 30537619
[TBL] [Abstract][Full Text] [Related]
9. Targeted delivery and controlled release of doxorubicin to cancer cells by smart ATP-responsive Y-shaped DNA structure-capped mesoporous silica nanoparticles.
Bagheri E; Alibolandi M; Abnous K; Taghdisi SM; Ramezani M
J Mater Chem B; 2021 Feb; 9(5):1351-1363. PubMed ID: 33447840
[TBL] [Abstract][Full Text] [Related]
10. Anti-Mucin1 Aptamer-Conjugated Chitosan Nanoparticles for Targeted Co-Delivery of Docetaxel and IGF-1R siRNA to SKBR3 Metastatic Breast Cancer Cells.
Jafari R; Majidi Zolbanin N; Majidi J; Atyabi F; Yousefi M; Jadidi-Niaragh F; Aghebati-Maleki L; Shanehbandi D; Soltani Zangbar MS; Rafatpanah H
Iran Biomed J; 2019 Jan; 23(1):21-33. PubMed ID: 30041514
[TBL] [Abstract][Full Text] [Related]
11. Aptamer-Dendrimer Bioconjugates for Targeted Delivery of miR-34a Expressing Plasmid and Antitumor Effects in Non-Small Cell Lung Cancer Cells.
Wang H; Zhao X; Guo C; Ren D; Zhao Y; Xiao W; Jiao W
PLoS One; 2015; 10(9):e0139136. PubMed ID: 26406332
[TBL] [Abstract][Full Text] [Related]
12. MUC1 aptamer-targeted DNA micelles for dual tumor therapy using doxorubicin and KLA peptide.
Charbgoo F; Alibolandi M; Taghdisi SM; Abnous K; Soltani F; Ramezani M
Nanomedicine; 2018 Apr; 14(3):685-697. PubMed ID: 29317345
[TBL] [Abstract][Full Text] [Related]
13. Lentivirus-mediated RNAi knockdown of NUPR1 inhibits human nonsmall cell lung cancer growth in vitro and in vivo.
Guo X; Wang W; Hu J; Feng K; Pan Y; Zhang L; Feng Y
Anat Rec (Hoboken); 2012 Dec; 295(12):2114-21. PubMed ID: 22961798
[TBL] [Abstract][Full Text] [Related]
14. Enhanced cancer therapy with pH-dependent and aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid) nanoparticles.
Saravanakumar K; Hu X; Shanmugam S; Chelliah R; Sekar P; Oh DH; Vijayakumar S; Kathiresan K; Wang MH
Arch Biochem Biophys; 2019 Aug; 671():143-151. PubMed ID: 31283911
[TBL] [Abstract][Full Text] [Related]
15. Aptamer-functionalized peptide H3CR5C as a novel nanovehicle for codelivery of fasudil and miRNA-195 targeting hepatocellular carcinoma.
Liu Y; Wu X; Gao Y; Zhang J; Zhang D; Gu S; Zhu G; Liu G; Li X
Int J Nanomedicine; 2016; 11():3891-905. PubMed ID: 27574422
[TBL] [Abstract][Full Text] [Related]
16. Specific targeting delivery to MUC1 overexpressing tumors by albumin-chitosan nanoparticles conjugated to DNA aptamer.
Esfandyari-Manesh M; Mohammadi A; Atyabi F; Nabavi SM; Ebrahimi SM; Shahmoradi E; Varnamkhasti BS; Ghahremani MH; Dinarvand R
Int J Pharm; 2016 Dec; 515(1-2):607-615. PubMed ID: 27989825
[TBL] [Abstract][Full Text] [Related]
17. Aptamer decorated hyaluronan/chitosan nanoparticles for targeted delivery of 5-fluorouracil to MUC1 overexpressing adenocarcinomas.
Ghasemi Z; Dinarvand R; Mottaghitalab F; Esfandyari-Manesh M; Sayari E; Atyabi F
Carbohydr Polym; 2015 May; 121():190-8. PubMed ID: 25659689
[TBL] [Abstract][Full Text] [Related]
18. MUC-1 aptamer targeted superparamagnetic iron oxide nanoparticles for magnetic resonance imaging of pancreatic cancer in vivo and in vitro experiment.
Zou Q; Zhang CJ; Yan YZ; Min ZJ; Li CS
J Cell Biochem; 2019 Nov; 120(11):18650-18658. PubMed ID: 31338877
[TBL] [Abstract][Full Text] [Related]
19. Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133.
Yin H; Xiong G; Guo S; Xu C; Xu R; Guo P; Shu D
Mol Ther; 2019 Jul; 27(7):1252-1261. PubMed ID: 31085078
[TBL] [Abstract][Full Text] [Related]
20. Suppression of Wnt signaling by the miR-29 family is mediated by demethylation of WIF-1 in non-small-cell lung cancer.
Tan M; Wu J; Cai Y
Biochem Biophys Res Commun; 2013 Sep; 438(4):673-9. PubMed ID: 23939044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
